Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy

To determine whether circulating gelsolin (GSN) levels in patients with ankylosing spondylitis (AS) undergoing TNF-α antagonist-infliximab-therapy are altered compared with controls and to establish whether disease activity, systemic inflammation and metabolic syndrome are potential determinants of...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental rheumatology 2014-03, Vol.32 (2), p.218-224
Main Authors: Genre, F, López-Mejías, R, Miranda-Filloy, J A, Ubilla, B, Carnero-López, B, Gómez-Acebo, I, Blanco, R, Ochoa, R, Rueda-Gotor, J, González-Juanatey, C, Llorca, J, González-Gay, M A
Format: Article
Language:English
Subjects:
Adipokines - metabolism
Adult
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antirheumatic Agents - administration & dosage
Antirheumatic Agents - adverse effects
Dose-Response Relationship, Drug
Drug Monitoring
Female
Gelsolin - metabolism
Humans
Inflammation - drug therapy
Infliximab
Infusions, Intravenous
Male
Metabolism - drug effects
Middle Aged
Outpatients
Patient Acuity
Sex Factors
Spondylitis, Ankylosing - drug therapy
Spondylitis, Ankylosing - metabolism
Spondylitis, Ankylosing - physiopathology
Statistics as Topic
Treatment Outcome
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine whether circulating gelsolin (GSN) levels in patients with ankylosing spondylitis (AS) undergoing TNF-α antagonist-infliximab-therapy are altered compared with controls and to establish whether disease activity, systemic inflammation and metabolic syndrome are potential determinants of circulating GSN levels in these patients. We assessed GSN serum concentrations in a series of 30 non-diabetic AS patients without cardiovascular (CV) disease undergoing TNF-α antagonist-infliximab therapy and 48 matched controls. GSN levels were measured immediately before and after an infliximab infusion. Correlations of GSN serum levels with disease activity, systemic inflammation and metabolic syndrome were assessed. Potential changes in GSN concentration following an infusion of anti-TNF-α monoclonal antibody-infliximab were also analysed. Although at the time of the study AS patients undergoing anti-TNF-α therapy had adequate control of the disease (mean BASDAI 2.94), they showed lower GSN serum levels than healthy controls (mean±SD: 38660.42±23624.6 ng/ml versus 68975.43±31246.79 ng/ml; p
ISSN:0392-856X